Trials / Completed
CompletedNCT01857908
A Correlative Study of Biomarkers of Resistance in Patients With Castrate Resistant Prostate Cancer Treated With Abiraterone
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (actual)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Adrenal androgens are serum biomarkers of interest that may help guide abiraterone acetate treatment, particularly at the time of progression. Biomarkers may also help identify pathways to resistance of abiraterone acetate treatment. The most practical way of approaching this question is to explore surrogate biomarkers of prostate cancer including quantification of pharmacodynamic endocrine biomarkers.
Detailed description
Goals of this study include: * Explore which circulating endocrine markers or endocrine related markers have the best potential to predict clinical response to abiraterone acetate in CRPC patients * Explore the utility of microRNA, circulating DNA and exosome analyses in complementing the previous objective
Conditions
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2014-11-01
- First posted
- 2013-05-20
- Last updated
- 2015-06-22
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT01857908. Inclusion in this directory is not an endorsement.